240,963 Shares in OnKure Therapeutics, Inc. $OKUR Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new stake in OnKure Therapeutics, Inc. (NASDAQ:OKUR) in the second quarter, HoldingsChannel.com reports. The fund purchased 240,963 shares of the company’s stock, valued at approximately $1,099,000.

Several other institutional investors and hedge funds have also bought and sold shares of OKUR. Vivo Capital LLC acquired a new position in shares of OnKure Therapeutics in the 1st quarter valued at approximately $7,981,000. Renaissance Technologies LLC boosted its position in shares of OnKure Therapeutics by 52.5% during the 1st quarter. Renaissance Technologies LLC now owns 377,250 shares of the company’s stock worth $1,562,000 after acquiring an additional 129,900 shares in the last quarter. ADAR1 Capital Management LLC boosted its position in shares of OnKure Therapeutics by 140.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock worth $10,081,000 after acquiring an additional 1,420,783 shares in the last quarter. Affinity Asset Advisors LLC bought a new position in OnKure Therapeutics in the first quarter valued at approximately $998,000. Finally, DV Trading LLC acquired a new position in OnKure Therapeutics during the first quarter valued at approximately $998,000. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Price Performance

OnKure Therapeutics stock opened at $3.58 on Friday. The business has a 50 day moving average of $4.09 and a 200-day moving average of $4.00. OnKure Therapeutics, Inc. has a 1 year low of $2.23 and a 1 year high of $5.38. The company has a market capitalization of $144.63 million, a P/E ratio of -1.02 and a beta of 0.23.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Tuesday, August 4th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.23. Equities analysts anticipate that OnKure Therapeutics, Inc. will post -1.71 EPS for the current year.

Analyst Upgrades and Downgrades

OKUR has been the subject of several recent analyst reports. Weiss Ratings cut OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Wall Street Zen raised OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. HC Wainwright dropped their price objective on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research report on Monday, July 20th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of OnKure Therapeutics in a research note on Friday, August 14th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, OnKure Therapeutics has a consensus rating of “Hold” and a consensus target price of $17.50.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.